New AIDS Therapy Nukes HIV
Radioactive Antibodies Seek and Destroy HIV Infected Cells in Mouse Study
WebMD News Archive
Curing HIV? continued...
But once treatment stops, the virus eventually comes back. That's because
HIV hides in a few long-lived cells -- so-called latent HIV infection.
If a person gets HAART treatment very, very soon after infection, it's
possible to stop the virus before it can establish hideouts. But there is a
very narrow window of opportunity to begin this treatment -- as little as a
day, and certainly within 72 hours of exposure.
That's because HAART has to work before it starts to replicate within cells.
But if radioimmunotherapy were available, the treatment could seek out infected
cells and kill them -- effectively widening the window of opportunity to
eliminate HIV infection.
Moreover, new strategies are being developed to flush HIV out of hiding.
Such strategies, combined with radioimmunotherapy and HAART, might conceivably
eradicate HIV, even in established infection. But that hope lies far in the
Dykes notes that the researchers haven't yet shown that radioimmunotherapy
can track down HIV anywhere in the body. She notes that in the current study,
the treatment hit HIV only in liver, spleen, and thymus cells.
"It will be interesting to see whether you could get the
radioimmunotherapy to target all the different areas that HIV gets to in the
body," she says. "I have a feeling this treatment probably wouldn't
cross the blood/brain barrier and get to HIV in the brain."
Dykes agrees with Goldstein that a major benefit of radioimmunotherapy would
be to help people for whom HAART simply doesn't work very well.
"A lot of patients out there don't have a lot of treatment options
left," Dykes says. "For those patients, this treatment -- which, after
all, involves radiation -- might be something they would be willing to
"While two-thirds of people with HIV respond well to HAART, others
don't," Goldstein says. "If we treat them with radioimmunotherapy to
reduce the number of infected cells, we may be able to take patients who are
not responsive and make them responsive to HAART."
Dadachova, Goldstein, and colleagues report their findings in the November
issue of the open-access, online journal PLOS Medicine.